Shionogi & Co. wants to kill it like a shinobi (i.e. ninja) in the night. The Japanese drug firm is a leading maker of antibiotics in its home country, with a full lineup of oral and injectable anti-infectives. It has been expanding its pipeline and its portfolio of marketed products to encompass other therapeutic areas as well, with programs in metabolic conditions and pain management. Through partnerships with large global firms, it owns Japanese market rights to some big name drugs, including AstraZeneca's blood pressure drug Crestor (which Shionogi helped develop); Purdue Pharma's pain therapy OxyContin; and Merck & Co. allergy medication Claritin.

Medifacts was founded in 1985 as Core Laboratory Services and has facilities in the US, Germany, and China. Medifacts International, Inc. company specializes in cardiovascular safety data management services, including ECG (electrocardiogram) and ambulatory blood pressure monitoring services, for clients conducting pharmaceutical, biotech, and medical device development trials. It also provides data collection, consulting, training, and telemedicine services. The company has sold its Clinical Research Services division, which offered broader data management services for clinical trials.

Kyorin, founded in 1923, already has affiliates and subsidiaries in Germany and the US. KYORIN Co., Ltd. is a Japan-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates in two business segments. The Pharmaceuticals segment is engaged in the manufacture, purchase and sale of pharmaceutical products, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the manufacture of clinical testing products, as well as the research of new drugs and candidate compounds. The Others segment is involved in the development and sale of cosmetics, as well as raw materials of medicines and cosmetics, the promotion of sales, the planning and production of advertisements, the sale of packaging materials, in addition to the provision of advisory services and the operational management of funds.

Teva Pharmaceutical Industries Limited company was founded in 1901 and is headquartered in Petach Tikva, Israel. Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories. The Company has a pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson’s disease and respiratory products. Teva’s active pharmaceutical ingredient business provides vertical integration to Teva’s own pharmaceutical production and sells to third party manufacturers. The Company’s global operations are conducted in North America, Europe, Latin America, Asia and Israel. Teva has operations in more than 60 countries, as well as 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 20 generic research and development centers operating mostly within certain manufacturing sites and 20 API manufacturing sites around the world. In January 2009, Phibro Animal Health Corporation completed the acquisition of the Abic Animal Health business from the Company.

Roche Colorado is one of the research, development, and manufacturing facilities of pharmaceutical giant Roche. Its R&D operations focus on developing efficient and high-quality production processes for manufacturing pharmaceutical ingredients and compounds. It has worked to bring to market such drugs as the anti-HIV treatments Fuzeon and Invirase and the influenza drug Tamiflu. Roche Colorado company also provides contract manufacturing of peptides, a protein-like compound used in pharmaceuticals. Roche Colorado is one of several US-based research and production facilities owned by Roche; affiliates include Hoffman-La Roche and Genentech.

Æterna Zentaris Inc. company was founded in 1991 and is headquartered in Quebec, Canada. Æterna Zentaris Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for endocrine therapy and oncology. Its lead product candidates in endocrinology are cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist that has completed Phase III trial for benign prostatic hyperplasia (BPH); and AEZS-130, an oral ghrelin antagonist in a Phase III trial as a diagnostic test for Growth Hormone Deficiency. Æterna Zentaris company's lead products in cancer are perifosine, a PI3K/Akt pathway inhibitor in Phase III for multiple myeloma, and AEZS-108, a Phase II clinical trial product for the treatment of advanced ovarian and endometrial cancers, as well as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma. Its pipeline also include compounds in pre clinical development, such as AEZS-115, an LHRH antagonist for endometriosis and urology; AEZS-120, an anti-cancer vaccine; AEZS-126 Erk and PI3K inhibitors for oncology; and AEZS-127 ErPC for oncology. Æterna Zentaris has partnership agreements with Shionogi and Co.; sanofi-aventis; Nippon Kayaku Co. Ltd.; Spectrum Pharmaceuticals, Inc.; Handok Pharmaceuticals Co., Ltd.; and Keryx Biopharmaceuticals, Inc.

Lectus Therapeutics Limited is a UK-based pharmaceutical company. Its mission is to build a development pipeline containing first-in-class ion channel therapeutics identified through the use of its proprietary proteomics technology for pain management and the treatment of urinary bladder disorders.Lectus, which began operations in the summer of 2003, exploits the power of its proprietary functional proteomics platform, LEPTICS® (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and builds on its knowledge of ion channels and protein-protein interactions, to identify and develop next-generation ion channel modulators that offer desirable clinical profiles with commensurate economic advantages.

Kreatech Biotechnology company develops tools used by pharmaceutical companies and medical researchers to detect and label RNA, DNA, and proteins. Its labeling kits, DNA probes, and other products are used in applications such as drug development and the diagnosis of disease. The company's investors include 3i Group, Alafi Capital, and Life Sciences Partners. Kreatech has formed alliances with many pharmaceutical and instrumentation firms, including heavyweights such as GE Healthcare Bio-Sciences and PerkinElmer.

MethylGene's endeavors in the field of medicine may earn it a good look. The company is developing enzyme inhibitors to treat cancer and various infectious diseases. It develops product candidates for treatments for ailments such as solid tumors and hematological malignancies. MethylGene has also researched therapies to battle conditions including fungal infections and antibiotic resistance. The company forms licensing and collaboration agreements with other pharmaceutical firms to further its development programs.

Quest PharmaTech aims to shed some light on dermatology and cancer treatments. Working with Hypocrellin, a photosensitive compound isolated from pigments found in fungi on bamboo, the company has developed its SonoLight Technology. The compound is relatively harmless until activated by light or ultrasound, whereupon it begins to destroy tissue. The company's pipeline of drug candidates include treatments to facilitate laser hair removal, address acne, and improve prostate cancer therapies. The company has sold off several earlier products to focus on its current pipeline and continues to consider strategic alternatives to facilitate its growth.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.